drugset
drugset / Trial / NCT02326779

Low-dose Aspirin Therapy for Esophageal Cancer

NCT02326779 ↗

Phase 3 Withdrawn Zhejiang University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the survival benefit of low-dose aspirin use for stage II-III esophageal cancer patients.

Timeline

Start
2016-03
Primary completion
2018-10
Completion
2018-12

Outcome

Outcome not reported

Stopped: “The study could not be performed.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg —

Indications

esophageal cancer